

**Department of Health**

**Residential Care Home Vaccination Programme**

|  |  |
| --- | --- |
|       | *(Name of the PID, to be filled by the DI)* |
|       | *(Date of issue of the Notice, to be filled by the DI)* |

**Notice of Objection to the Administration of Influenza Vaccine
to a Non-Institutionalised Person with Intellectual Disability (PID) Receiving Service in a Designated Institution (DI)**

The above-named PID, currently receiving service in       *(name of the DI, to be filled by the DI),* has been assessed by a doctor to be suitable for receiving vaccination. As the PID is unable to give consent for vaccination, your view (parent/guardian/relative) is consulted.

The information on influenza vaccine is attached for your reference (Annex 1). If you have considered and understood that not receiving vaccination will increase the risk of serious illness or even death should the PID get influenza infection, but object to the administration of vaccine to the PID nonetheless, please return the completed “Reply Slip –Objection to the Administration of Influenza Vaccine to a Non-Institutionalised Person with Intellectual Disability Receiving Service in a Designated Institution” (Annex 2) to the DI concerned[[1]](#footnote-1) before       (*two weeks from the date of issue of this Notice, to be filled by the DI*) to indicate that you clearly object to the administration of influenza vaccine to the above-named PID. Otherwise, the visiting medical officers will administer the vaccine to the above-named PID as necessary and appropriate based on the PID’s best interest.

For enquiries, please contact the DI staff concerned.

Department of Health (DH)

2023

(Letter to be issued by DIs on behalf of DH)

**Residential Care Home Vaccination Programme 2023/24**

**Information about Seasonal Influenza Vaccination**

**Benefits of Getting Seasonal Influenza Vaccination**

Respiratory infection caused by seasonal influenza is common. Persons with weakened immunity and elderly persons get infected, it can be a serious illness and may be complicated by bronchitis, pneumonia, or even death in the most serious cases. Influenza predisposes individuals to community-acquired bacterial pneumonia. Secondary bacterial pneumonia has been an important cause of morbidity and mortality for those infected with influenza. Seasonal influenza vaccination is one of the effective means to prevent seasonal influenza and its complications, as well as reduce influenza related hospitalisation and death.

**Seasonal Influenza and Vaccination**

Influenza is an acute illness of the respiratory tract caused by influenza viruses. It can be caused by various types of influenza viruses. In Hong Kong, the two subtypes of influenza A virus, H1N1 and H3N2, and influenza B virus, are most commonly seen. Influenza occurs in Hong Kong throughout the year, but is usually more common in periods from January to March/April and from July to August. The virus mainly spreads by respiratory droplets. The disease is characterised by fever, sore throat, cough, runny nose, headache, muscle aches and general tiredness. It is usually self-limiting with recovery in two to seven days. However, if persons with weakened immunity and elderly persons get infected, it can be a serious illness and may be complicated by bronchitis, pneumonia, encephalopathy, or even death in the most serious cases. Serious infection or complications can also occur in healthy individuals.

* **Seasonal Influenza Vaccine Composition**

The egg-based quadrivalent influenza vaccine provided under Residential Care Home Vaccination Programme (RVP) 2023/24 contains the following:

* an A/Victoria/4897/2022 (H1N1)pdm09-like virus
* an A/Darwin/9/2021 (H3N2)-like virus
* a B/Austria/1359417/2021 (B/Victoria lineage) -like virus
* a B/Phuket/3073/2013 (B/Yamagata lineage) -like virus

Inactivated seasonal influenza vaccine is used under RVP 2023/24.

* **Recommended Dose**

For persons aged 9 years or above, only one dose of seasonal influenza vaccine is required in each influenza season.

To ensure adequate immunity against seasonal influenza, children under 9 years of age who have never received any seasonal influenza vaccination before are recommended to receive 2 doses of seasonal influenza vaccine with a minimum interval of 4 weeks in the 2023/24 season. Children below 9 years of age, who have received at least one dose of seasonal influenza vaccine before are recommended to receive one dose of seasonal influenza vaccine in the 2023/24 season.

* **Who should not receive inactivated influenza vaccination**

People who have a history of severe allergic reaction to any vaccine component or a previous dose of any influenza vaccine are not suitable to have inactivated seasonal influenza vaccination. Individuals with mild egg allergy who are considering an influenza vaccination can be given inactivated influenza vaccination in primary care setting. Individuals with a history of anaphylaxis to egg should have seasonal influenza vaccine administered by healthcare professionals in appropriate medical facilities with capacity to recognise and manage severe allergic reactions. Influenza vaccine contains ovalbumin (an egg protein), but the vaccine manufacturing process involves repeated purification and the ovalbumin content is very low. Even people who are allergic to eggs are generally safe to receive vaccination. Those with bleeding disorders or on anticoagulants should consult their doctors for advice. If an individual suffers from fever on the day of vaccination, vaccination should be deferred till recovery.

* **Why should pregnant women receive seasonal influenza vaccination**

Seasonal influenza vaccination is recommended for all pregnant women for benefits in terms of reduced acute respiratory infection for both mothers and infants, and reduction of cardiopulmonary complications and the associated hospitalisations in pregnant women. The World Health Organization considers inactivated influenza vaccine (IIV) to be safe in pregnancy and there is no evidence showing that IIV can cause abnormality in foetus even if given during the first trimester. Recombinant influenza vaccine is not contraindicated in pregnancy. However, pregnant women should NOT receive live attenuated influenza vaccine because it contains live viruses. Pregnant women should consult a doctor for any queries. Inactivated influenza vaccine is used under RVP 2023/24.

* **What are the possible side effects following inactivated influenza vaccine administration**

Inactivated influenza vaccine is very safe and usually well tolerated apart from occasional soreness, redness or swelling at the injection site. Some recipients may experience fever, muscle pain, and tiredness beginning 6 to 12 hours after vaccination and lasting for up to two days. If fever or discomforts persist, please consult a doctor. Immediate severe allergic reactions like hives, swelling of the lips or tongue, and difficulties in breathing are rare and require emergency consultation. Influenza vaccination may be rarely followed by serious adverse events such as Guillain-Barré Syndrome (GBS) (about 1 to 2 case per million vaccines) and severe allergic reaction (anaphylaxis) (9 per 10 million doses distributed). However, influenza vaccination may not necessarily have causal relations with these adverse events. Studies have shown that the risk of GBS after influenza infection (17.20 per million infected persons) is much higher than after influenza vaccination (1.03 per million vaccine recipients).

* **Can COVID-19 vaccine be given together with seasonal influenza vaccine?**

COVID-19 vaccines can be co-administered with, or at any time before or after, seasonal influenza vaccine (including inactivated influenza vaccine, live attenuated influenza vaccines and recombinant influenza vaccine) under informed consent. If clients / parents of children wish to space out COVID-19 vaccine with seasonal influenza vaccine, an interval of 14 days is sufficient.

* **What to do if I feel discomfort after the co-administration of COVID-19 vaccine and seasonal influenza vaccine?**

In general, common side effects of both vaccines are usually mild and temporary which include soreness, redness and swelling at the injection site. Some people may experience fever, muscle pain, and fatigue a few hours after vaccination. In most cases, these symptoms would subside within a few days. If symptoms persist, or if allergic reactions (such as hives or facial swelling) or serious side effects occur, you should seek medical advice promptly.

Updated in July 2023



**Department of Health**

**Residential Care Home Vaccination Programme**

**Reply Slip**

**Objection to the Administration of Influenza Vaccine**

**to a Non-Institutionalised Person with Intellectual Disability (PID) Receiving Service in a Designated Institution (DI) [[2]](#footnote-2)1**

|  |  |  |
| --- | --- | --- |
| Name of the DI | : |       |
| Name of the PID | : |       |

I am the **\*parent/guardian/relative** of the above-name PID and learnt that the above-named PID was assessed to be suitable for receiving vaccination. I **object to the administration of the influenza vaccine to the above-named PID**.

I understand that not receiving vaccination will increase the risk of hospitalisation due to serious illness or even death should the PID get infected, and will pose threats to other service users, staff of the DI and the overall operation of the DI.

I understand that I have to return this Reply Slip within 14 days from the date of issue of the Notice. Otherwise, the visiting medical officers will administer the vaccines to the above-named PID as necessary and appropriate based on the PID’s best interest.

|  |  |
| --- | --- |
| Signature of the PID’s parent/guardian /relative\*: |  |
| Name of the PID’s parent guardian/ /relative\*: |       |
| Contact number: |       |
| Date: |       |

*\* Delete whichever is inappropriate*

1. The parent/guardian/relative may return the Reply Slip to the DI concerned by their normal means of communication (e.g. in person, SMS, mail, fax or e-mail etc.). [↑](#footnote-ref-1)
2. 1 The parent/guardian/relative may return the Reply Slip to the DI concerned by their normal means of communication (e.g. in person, SMS, mail, fax or e-mail etc.). [↑](#footnote-ref-2)